Relief Therapeutics Sells GOLIKE Rights, Shifts Focus to R&D

Relief Therapeutics Holding SA has finalized the sale of its GOLIKE intellectual property and commercialization rights outside the United States to Nutrisens. This move marks the completion of Relief's transition from a direct sales model to a partnership-based approach. The company aims to redirect efforts towards research and development (R&D) and licensing commercialized products.

The agreement allows Nutrisens to manage marketing and sales for European markets and other international regions, while Relief retains GOLIKE rights in the U.S. Nutrisens' expertise is expected to enhance patient support globally, excluding the U.S.

Relief received CHF 1.2 million upfront and expects further contingent payments, securing a cash balance of CHF 15.3 million. This financial stability positions Relief to advance R&D in areas such as rare dermatology and potential expansion into gastrointestinal therapies.